Excluding R&D, Q1 Margins At 28%: Biocon
  • Saba Ashraf
  • Jul 26 2013

July 26: Bloomberg TV India asks Biocon Chairman and MD Kiran Mazumdar Shaw about the company’s outlook. She says the company aims to maintain healthy EBITDA margins, which will allow Biocon to continue investing in its R&D programmes.